

Rituximab

S

Humoral immune defect and negative seroconversion IgG-spike 1 test: case report

In a multicentric, observational, prospective study of 115 patients with multiple sclerosis (MS) vaccinated against COVID-19 in Chile, a patient [*age and sex not stated*] was described, who experienced humoral immune defect and showed negative seroconversion IgG-spike 1 test during treatment with rituximab for MS [*route, dosage and time to reaction onset not stated*], and the patient therefore developed COVID-19 despite full vaccination. The patient required hospitalisation along with 1 day of non-invasive mechanical ventilation [*outcome not stated*].

Ciampi E, et al. Safety and seroconversion rates of mRNA and inactivated vaccines against SARS-COV-2 AMONG patients with multiple sclerosis: A multicentric observational study. *Multiple Sclerosis Journal* 28: NP8 abstr. 0034, No. 2, Feb 2022. Available from: URL: <http://doi.org/10.1177/13524585211052173> [abstract] 803645512